About the Company
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MYOK News
BMS bulks up in cardio with $13.1bn takeover deal for MyoKardia
Bristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step up in its development of cardiovascular drugs. The all-cash deal is mainly about MyoKardia ...
Bristol-Myers Shares Gain After Positive Data From Opdivo Lung Cancer Trial
Earlier this week, Britsol-Myers agreed to buy drugmaker MyoKardia Inc. (MYOK) , which makes the experimental heart treatment mavacamten, for around $13.1 billion and reiterated its existing ...
FULC Fulcrum Therapeutics, Inc.
and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge ...
Stock Market Today With Jim Cramer: Stimulus For Airlines
Its much larger than $13 billion." On Monday, Britsol-Myers Squibb Co. agreed to buy drugmaker MyoKardia Inc. which makes the experimental heart treatment Mavacamten, for around $13.1 billion.
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
Shares of Avidity Biosciences, Inc. RNA surged 14.9% following the ... Avidity announced a research collaboration with MyoKardia in 2021 to demonstrate the potential utility of antibody oligonucle ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
Starwood Property Trust Inc.
Annaly Capital Management Inc. 6.5% Conv. Pfd. Series G-0.52% Annaly Capital Management Inc. Pfd. Series I-0.26% Annaly Capital Management Inc. 6.95% Cum. Redeem. Pfd. Series F-0.24% ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Snap Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Apple Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Apple Inc. (AAPL)
Shares of Apple (AAPL) are trading lower after Needham's Laura Martin lowered estimates for the tech giant to reflect iPhone sales concerns and weakness in China. The estimates are offset by ...
Fulcrum Therapeutics Inc (FULC)
Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week: upgrades for Netflix, Fulcrum Therapeutics, and Grab Holdings, and downgrades for Medical... Fulcrum ...
Loading the latest forecasts...